Safety Pharmacology Society Webinar: Simon Authier, DVM, MBA, PhD Director - Safety Pharmacology and Veterinary Science CIToxLAB North America
|
|
- Marion Greer
- 6 years ago
- Views:
Transcription
1 Safety Pharmacology Society Webinar: Simon Authier, DVM, MBA, PhD Director - Safety Pharmacology and Veterinary Science CIToxLAB North America
2 Agenda Introduction GI presentation rescheduled Upcoming SPS Event DSPS Accreditation Program Expert presentation: Thomas J Hudzik, Ph.D. Real-time survey Open discussions Closing remarks
3 Introduction FDA Draft Guidance for Industry Assessment of Abuse Potential of Drugs UCM pdf (Published January 27, 2010)
4 Introduction Drug abuse is the non-medical use of a prescription drug most of the time for positive subjective effects Clinically relevant dose levels are not applicable Drug dependence is the need to continue taking a drug to avoid withdrawal effects (e.g. SSRI)
5 Introduction Drug development industry aims to identify abuse potential as early as possible Commercial impact of drug scheduling (limited prescription) Drug abuse may apply to small molecules/chemicals or biotherapeutics When should an «abuse package» be submitted? If the drug affects the CNS, is chemically or pharmacologically similar to other drugs with known abuse potential, or produces psychoactive effects such as sedation, euphoria, and mood changes.(fda Guidance document)
6 Introduction Drug abuse liability studies are usually recognized for relatively high predictivity to the human response compared to other non-clinical models but there remains several challenges in the field A variety of pharmacological, regulatory and medical considerations need to be evaluated and the approach should be tailored to each drug candidate All drug candidates with CNS effect (intentional or not), will need to be evaluated for drug abuse potential
7 Introduction Several source of non-clinical abuse data: Chemical analysis and structural similarities In vitro assays (e.g. receptor ligand and functional endpoints) PKPD profile in animal species (brain:plasma ratio) Animal behavioral and physiological evaluations (including toxicology studies) Non-clinical Abuse Potential Studies: Self-administration Drug discrimination Physical dependence and withdrawal
8 Introduction Safety pharmacology endpoints may increased sensitivity in detecting withdrawal signs with technologies such as telemetry that enables continuous monitoring of parameters such as: Heart rate Arterial pressures Respiratory rate Body temperature Activity level
9 A Glance at an Interesting Scientific Program Reducing Safety Related Attrition - Increasing Likelihood of Success: - Target Related Safety - Chemistry (molecule) & Off-target (selectivity) Related Safety - Novel Approaches to Safety Screening Expanding the Frontiers of Safety Pharmacology: - Support to Late Stage Drug Development (Phase II onwards) - Safety Assessment Evaluation of Nonconventional Therapeutic Modalities - Safety Pharmacology beyond Small Molecules -Best Practice Comparing Safety Pharmacology as stand alone to SP-endpoint inclusion in Toxicology Pharma, Regulators and Academia
10 Diplomate of Safety Pharmacology Society Various Accreditations are available in Toxicology (DABT and ERT) The Safety Pharmacology Society will launch a Certification specific to our field: Diplomate of Safety Pharmacology Society: DSPS First Accreditation Examination on September 15th, 2013 at the SPS Annual Meeting 2013 in Rotterdam Information on the DSPS program will be on the SPS website on May 30, Scope of the Accreditation (scientific areas and literature references) - Process to take and maintain the DSPS Accreditation
11 Diplomate of Safety Pharmacology Society Regulatory guidelines (10%) Cardiovascular safety pharmacology Electrophysiology (20%) Hemodynamy and contractility (10%) Neurological safety pharmacology General neurological evaluations (15%) Drug abuse potential (2%) Seizure liabilities (3%) Respiratory safety pharmacology (15%) Renal safety pharmacology (5%) Gastrointestinal safety pharmacology (5%) Other systems and models (5%) Cross discipline knowledge (10%) Physiology Pharmacokinetics Toxicology Dosing formulation and Analytical methods Immunology
12 Slides of expert panel members
Assessing the Clinical Abuse Potential of Abuse Deterrent Opioid Formulations
Assessing the Clinical Abuse Potential of Abuse Deterrent Opioid Formulations November 16, 2016 Beatrice Setnik, PhD VP, Clinical Pharmacology, Early Phase INC Research Disclosure I am an employee of INC
More informationOpportunities in Pain Research with the NIH HEAL Initiative
Opportunities in Pain Research with the NIH HEAL Initiative Clinton Wright, M.D. Director, Division of Clinical Research National Institute of Neurological Disorders and Stroke, NIH September 20, 2018
More informationNIH HEAL Initiative: Program Update and Funding Opportunities for Pain Research Available through NIH
NIH HEAL Initiative: Program Update and Funding Opportunities for Pain Research Available through NIH AAMC Webinar November 8, 2018 Walter J. Koroshetz, MD Director, National Institute of Neurological
More informationCiPA, Pre-clinical Testing. Derek Leishman PhD DSP & ICH S7B
CiPA, Pre-clinical Testing Derek Leishman PhD DSP & ICH S7B Outline Introduction Scenarios Conclusion Expressing an opinion What is not covered? Analysis/critique of the components too little time to try
More informationGDUFA: 2 ½ years later Impact & Importance
GDUFA: 2 ½ years later Impact & Importance Georgia Hizon Manager, Regulatory Publications Fresenius Kabi USA, LLC Disclaimer The views and opinions expressed in the following PowerPoint slides are those
More informationNo! No! No! No! With the possible exception of humans Public Health Question Does the compound have the potential to be abused? Public Health Question Does the compound have the potential to be abused?
More informationSUBSTANCE USE DISORDERS
THE POWER OFx SUBSTANCE USE DISORDERS Experts. Experience. Execution. Deep Dive: Substance Use Disorder Clinical Research Accelerate your next substance use disorder study with Medpace s noted medical
More informationName of the Substance
Name of the Substance 0. Do you have any information on the use of this substance in your country either for medical, scientific, industrial or other professional purposes, for non-medical consumption
More informationSafety Pharmacology Post Meeting Survey 2014
Q1 Please enter your personal information below. (If you want to be included in the 2014 Annual Meeting survey for a chance to win $200, this information is REQUIRED) Answered: 132 Skipped: 14 Name: Company:
More informationDeveloping a Target Product Profile for a Preventive HIV Vaccine
Developing a Target Product Profile for a Preventive HIV Vaccine Topics to be Covered Overview of TPPs What are they? What is the purpose and benefit of using a TPP? What is usually in a TPP? What are
More informationMorphine Sulfate Hydromorphone Oxymorphone
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.02.33 Subject: Morphine Drug Class Page: 1 of 8 Last Review Date: June 19, 2015 Morphine Sulfate Hydromorphone
More informationPrepublication Requirements
Issued Prepublication Requirements The Joint Commission has approved the following revisions for prepublication. While revised requirements are published in the semiannual updates to the print manuals
More informationCore Peer Competencies Take Center Stage of Integrating Peers in the Mental Health Workforce. NAMI National Conference Denver, CO.
Core Peer Competencies Take Center Stage of Integrating Peers in the Mental Health Workforce NAMI National Conference Denver, CO July 7, 20156 1 Overview of Core Peer Competencies Keris Jän Myrick, M.B.A.,
More informationOXYCONTIN Diversion & Abuse Drug Enforcement Administration Office of Diversion Control October 2003
OXYCONTIN Diversion & Abuse Office of Diversion Control October 2003 OXYCONTIN OxyContin is a controlled release form of Schedule II oxycodone Manufactured in tablet form and intended for oral ingestion
More informationSOMNUS VITM Supplement for sleep and wellness
SOMNUS VITM Supplement for sleep and wellness Unscheduled and non-psychoactive, CANNABINOL represents a major market opportunity as a sedative as well as a potential treatment for insomnia, anxiety and
More informationCognitive effects of opioids safe to drive?
Cognitive effects of opioids safe to drive? Jason Boland Senior Clinical Lecturer and Honorary Consultant in Palliative Medicine Wolfson Palliative Care Research Centre, Hull York Medical School, University
More information25/03/2014. Workshop Overview. Hot Topics in FDA Regulations and Pharmacotherapy Research that Impact Patient Care:
Hot Topics in FDA Regulations and Pharmacotherapy Research that Impact Patient Care: Sharon L. Walsh, Ph.D. Shanna Babalonis, Ph.D. Michelle Lofwall, M.D. Center on Drug and Alcohol Research Department
More informationPK/PD analysis in assessment of abuse deterrence
PK/PD analysis in assessment of abuse deterrence Megan J. Shram, PhD Director and Principal, Altreos Research Partners Inc. Adjunct Professor and Lecturer, Department of Pharmacology, University of Toronto
More informationRisk and Benefit Assessments for Optimal Dose Selection Based on Exposure Response
Risk and Benefit Assessments for Optimal Dose Selection Based on Exposure Response 2003 FDA/Industry Statistics Workshop Peter I. Lee, PhD Associate Director, Pharmacometrics OCPB, CDER, FDA Disclaimers
More informationREHABILITATION SCIENCE (RHBS)
Rehabilitation Science (RHBS) 1 REHABILITATION SCIENCE (RHBS) 200 Level Courses RHBS 201: Introduction to 3 credits. Introduces the field of rehabilitation science. Surveys various topics within rehabilitation
More informationMigraine: Developing Drugs for Acute Treatment Guidance for Industry
Migraine: Developing Drugs for Acute Treatment Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2018
More informationThe EU PIP - a step in Pediatric Drug Development. Thomas Severin Bonn,
The EU PIP - a step in Pediatric Drug Development Thomas Severin Bonn, 13.01.2009 Agenda Implications for Industry Company Preparation Time of PIP Submission Content of the PIP The PIP Process and first
More informationGuidance for Industry
MEDICAL DEVICES SECTOR Guidance for Industry Format and Content of Proposed Bundling/Grouping Criteria for Medical Devices DRAFT GUIDANCE This guidance document is being distributed for comment purposes
More information9/20/2011. Impact of EU Paediatric Regulation on drug development and Marketing authorisations Industry experience
Impact of EU Paediatric Regulation on drug development and Marketing authorisations Industry experience Judith Creba Head EU Liaison and Policy, DRA Novartis Pharma AG, Switzerland Disclaimer The views
More informationPesticide Inert Ingredient Activities
Pesticide Inert Ingredient Activities CPDA Regulatory Policy Conference Program March 13, 2018 P. V. Shah, Ph.D Chief, Chemistry, Inerts and Toxicology Assessment Branch (CITAB) Registration Division Office
More informationThe regulatory landscape Stephen White on behalf of the EBF
The regulatory landscape Stephen White on behalf of the EBF http://www.europeanbioanalysisforum.eu Overview 1. MIST and DDI Guideline 2. Regulatory landscape for BA 3. Tiered Approach on BA of metabolites
More informationBioequivalence Requirements: USA and EU
Bioequivalence Requirements: USA and EU Dr. Nicholas Cappuccino Chair, IGPA Science Committee Global Head of Quality, Dr. Reddy s Laboratories Ltd. 15 th Annual IGPA Conference Kyoto, Japan December 6,
More informationFebruary 23, Q4 and Year-End 2016 Financial Results
February 23, 2017 Q4 and Year-End 2016 Financial Results 2 RETHINKING CNS Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Jim Doherty, Ph.D.,
More informationNEUROSCIENCE. THE POWER OFx. Experts. Experience. Execution. A Deeper Dive into Neurology. Scientifically-Driven Clinical Development
THE POWER OFx Experts. Experience. Execution. A Deeper Dive into Neurology Medpace supports our sponsors who are advancing new neurological products by providing specialized expertise in the design and
More informationStrategies in Managing Opioid and Benzodiazepine Co-Prescribing
Strategies in Managing Opioid and Benzodiazepine Co-Prescribing Scott Endsley, MD Associate Medical Director, Quality Partnership HealthPlan of California October 25, 2016 Audio Instructions To avoid echoes
More informationAssessing Drug Safety
Assessing Drug Safety Paul J. Seligman, MD, MPH Director Office of Pharmacoepidemiology & Statistical Science Center for Drug Evaluation & Research July 20, 2005 Institute of Medicine Committee 1 Agenda
More informationGuidance for Industry
Guidance for Industry Assessment of Abuse Potential of Drugs DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document
More informationNovember 2, Q Financial Results
November 2, 2017 Q3 2017 Financial Results Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationUpdate on the Clinical Outcome Assessment Qualification Program and COA Compendium
Update on the Clinical Outcome Assessment Qualification Program and COA Compendium Seventh Annual PRO Consortium Workshop April 27-28, 2016 Michelle Campbell, PhD Clinical Outcomes Assessment Staff (COA
More informationTOBACCO PRODUCT OR MEDICAL PRODUCT?
TOBACCO PRODUCT OR MEDICAL PRODUCT? Priscilla Callahan-Lyon, MD Deputy Director Division of Individual Health Science Office of Science, CTP Grail Sipes, JD Director Office of Regulatory Policy, CDER Disclaimer:
More informationThe Sale of Cannabis in Pharmacies. Michael H. Ghobrial, PharmD, JD Associate Director, Health Policy American Pharmacists Association
The Sale of Cannabis in Pharmacies Michael H. Ghobrial, PharmD, JD Associate Director, Health Policy American Pharmacists Association Development This activity was developed by the American Pharmacists
More informationOptimizing Suboxone in Opioid Addicts
Optimizing Suboxone in Opioid Addicts David Chim, D.O. Integrated Substance Abuse Programs Dept. of Psychiatry, UCLA K30 Translational Research Interest March 24, 2009 dchim@mednet.ucla.edu www.uclaisap.org
More informationSlide 1. Slide 2. Slide 3. Opioid (Narcotic) Analgesics and Antagonists. Lesson 6.1. Lesson 6.1. Opioid (Narcotic) Analgesics and Antagonists
Slide 1 Opioid (Narcotic) Analgesics and Antagonists Chapter 6 1 Slide 2 Lesson 6.1 Opioid (Narcotic) Analgesics and Antagonists 1. Explain the classification, mechanism of action, and pharmacokinetics
More informationPHARMACEUTICAL SCIENCES (PHM SCI)
Pharmaceutical Sciences (PHM SCI) 1 PHARMACEUTICAL SCIENCES (PHM SCI) PHM SCI 310 DRUGS AND THEIR ACTIONS Introduces students to the biological effects of drugs on human health. Emphasis on how drugs,
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationOPIOID IR COMBO DRUGS. Oxycodone-acetaminophen, Oxycodone-aspirin, Oxycodone-ibuprofen, Tramadolacetaminophen
RATIONALE FOR INCLUSION IN PA PROGRAM Background Apadaz (benzhydrocodone-acetaminophen), codeine-acetaminophen, dihydrocodeine-caffeineacetaminophen, hydrocodone-acetaminophen, hydrocodone-ibuprofen, oxycodoneacetaminophen,
More informationDocuments Regarding Drug Abuse Assessments
Overview of the FDA Guidance Documents Regarding Drug Abuse Assessments ABUSE DETERRENT FORMULATION SCIENCE MEETING DISCUSSION OF THE FDA DRAFT GUIDANCE FOR INDUSTRY: ABUSE DETERRENT OPIOIDS EVALUATION
More informationOctober 15, Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852
Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Re: Docket No. FDA-2012-N-0548 To Whom It May Concern: The American Dental Association
More informationTHE FDA DRUG APPROVAL PROCESS Under the Federal Food, Drug, and Cosmetic (FD&C) Act, FDA is responsible for ensuring that all new drugs are safe and
THE FDA DRUG APPROVAL PROCESS Under the Federal Food, Drug, and Cosmetic (FD&C) Act, FDA is responsible for ensuring that all new drugs are safe and effective. Before any drug is approved for marketing
More informationNaloxone Expanded Access: OTC status Considerations for a Nonprescription Drug Development Program
Naloxone Expanded Access: OTC status Considerations for a Nonprescription Drug Development Program Andrea Leonard-Segal, M.D., M.S. Director, Division of Nonprescription Clinical Evaluation 1 Contents
More informationCorporate Presentation Asia Investment Series March 2018
Corporate Presentation Asia Investment Series March 2018 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within the meaning of the United
More informationGLOBAL BIOANALYSIS CONSORTIUM
GLOBAL BIOANALYSIS CONSORTIUM Scope and Regulations Harmonization Team: A1 (Work in Progress) John Smeraglia on behalf of the HT-A1 A1: Scope and regulations Team members: Team lead Region Expertise Surendra
More informationNonclinical Safety Evaluation of Inhalation Drug Products
Nonclinical Safety Evaluation of Inhalation Drug Products February 13, 2002 Life Science Research Organization Bethesda, Maryland Luqi Pei, Ph.D. Division of Pulmonary and Allergy Drug Products Center
More informationCERTIFICATE IN SPECIAL CARE DENTAL NURSING
NATIONAL EXAMINING BOARD FOR DENTAL NURSES CERTIFICATE IN SPECIAL CARE DENTAL NURSING PROSPECTUS 108-110 LONDON STREET FLEETWOOD LANCASHIRE FY7 6EU NEBDN is a limited company registered in England & Wales
More informationInternational Regulatory Environment for the Abuse Liability Evaluation
International Regulatory Environment for the Abuse Liability Evaluation Conference on Preclinical Abuse Liability Testing, October 19-20, 2006, Annapolis MD. Willem Scholten PharmD, MPA Quality Assurance
More informationThe Codex Alimentarius
The Codex Alimentarius Herman B.W.M. Koëter, MSc, DTox, ERT Managing Director and Executive Secretary of the Management Board,, vzw Codex Alimentarius A joint WHO/FAO Food Standards Programme; 171 member
More informationPOISONS SCHEDULING. Monique Reyes Senior Pharmaceutical Officer Pharmaceutical Regulatory Unit NSW Ministry of Health
POISONS SCHEDULING Monique Reyes Senior Pharmaceutical Officer Pharmaceutical Regulatory Unit NSW Ministry of Health Topics Schedules of the Poisons Standard (Cth) Poisons and Therapeutic Goods Act 1966
More informationThe Evolution of Abuse Deterrent Drug Formulations: Testing Effectiveness from the Benchtop to the Real World
The Evolution of Abuse Deterrent Drug Formulations: Testing Effectiveness from the Benchtop to the Real World Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Center Executive Director,
More informationCFSAN Update Michael M. Landa
CFSAN Update Comments by Michael M. Landa Director, Center for Food Safety and Applied Nutrition JIFSAN Fall Advisory Council Meeting November 14, 2013 1 CFSAN Plan for Program Priorities (2013 2014) Reduce
More informationJOIN US TO INTEGRATE CLINICAL RESEARCH AND HEALTH CARE
JOIN US TO INTEGRATE CLINICAL RESEARCH AND HEALTH CARE #BridgeTheGap April 4-5, 2018 National Harbor, MD bridgingclinical.com LET'S BUILD A BRIDGE Work with us to bridge the gap between clinical research
More informationEmergency Department Suite
Emergency Department Suite This suite of Pediatric Learning Solutions (PLS) online courseware and curriculums provides 24/7 access to the foundational knowledge and just-in-time job aids clinicians working
More informationCancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development One Washington Circle Hotel, Washington, DC October 19-21, 2016
Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development One Washington Circle Hotel, Washington, DC 20037 October 19-21, 2016 Wednesday, October 19, 2016 7:30 8:30 AM Registration
More informationGeneric Drug Approval Process
1 Generic Drug Approval Process Sharon Ricciardo Katherine P. Weld. M.S., Ph.D. AAVPT Veterinary Drug Regulatory Life Cycle Course March 2, 2011 Overview Background Approval Process Bioequivalence Special
More informationExpert Peer Review for Carfentanil
Expert Committee on Drug Dependence Thirty-ninth Meeting Geneva, 6-10 November 2017 Expert Peer Review for Carfentanil 1. Comments based on the review report a. Evidence on dependence and abuse potential
More informationSpontaneous canine malignancies: Models for precision cancer medicine
National Cancer Institute Spontaneous canine malignancies: Models for precision cancer medicine Amy K. LeBlanc, DVM DACVIM (Oncology) Director, NCI Comparative Oncology Program NIH/NCI Center for Cancer
More informationMEA assays using human ipsc-derived cardiomyocytes; challenges and opportunities
MEA assays using human ipsc-derived cardiomyocytes; challenges and opportunities Event Presenter Date EMA Workshop 2017 Tessa de Korte, MSc 2017, October 5 Page 1 Ncardia at a glance Foundation Ncardia
More informationCognitive Research Corporation
Cognitive Research Corporation Contract Research Organization offering specialized expertise to fit the unique needs of each client Bobbie Theodore clinicaltrials@alliancesites.com An Alliance of Quality
More informationBioavailability trial design for products delivered via the inhalation route
Bioavailability trial design for products delivered via the inhalation route Jianmeng Chen, Suresh Doddapaneni, Ping Ji, Chandrahas G Sahajwalla Division of Clinical Pharmacology 2 US FDA/CDER/OTS/OCP
More informationADVANCED THERAPIES IN THE CNS: TIME TO GET SMART
ADVANCED THERAPIES IN THE CNS: TIME TO GET SMART Moderator: Panelists: Joel Sandler, PhD, Assoc. Principal, Defined Health Steven Gray, PhD, Assoc. Professor, UT Southwestern Mike Rice, MS, MBA, Principal,
More informationDISPENSING OR SELLING NALOXONE. Guidance for pharmacy professionals when dispensing or selling naloxone as a Schedule II drug.
DISPENSING OR SELLING NALOXONE Guidance for pharmacy professionals when dispensing or selling naloxone as a Schedule II drug. UPDATED ON: April 21, 2017 Purpose The intent of this document is to provide
More informationFood additives. FAO guidelines on the structure and content of the document called "Chemical and Technical Assessment (CTA)" Rome, February 2003
FAO Joint Secretariat to JECFA Joint FAO/WHO Expert Committee on Food Additives Food additives FAO guidelines on the structure and content of the document called "Chemical and Technical Assessment (CTA)"
More informationSTUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS
More informationMETHODOLOGIES FOR INTERMITTENT AND SHORT-TERM EXPOSURE TO CARCINOGENS SUBCOMMITTEE
METHODOLOGIES FOR INTERMITTENT AND SHORT-TERM EXPOSURE TO CARCINOGENS SUBCOMMITTEE Mission The mission of the MISTEC Subcommittee is to develop methodologies for establishing appropriate dose-metrics to
More informationPHARMACY PRACTICE (PHM PRAC)
Pharmacy Practice (PHM PRAC) 1 PHARMACY PRACTICE (PHM PRAC) PHM PRAC 305 CONSUMER SELF-CARE AND OVER-THE-COUNTER DRUGS Provides learners with information regarding self-care of common, minor health conditions.
More informationCancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development MicroTek Training Center Washington, DC October 17 19, 2018
Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development MicroTek Training Center Washington, DC October 17 19, 2018 Wednesday, October 17, 2018 8:00 8:30 AM Registration and Continental
More informationClinical Perspective on Conducting Trials in Major Depressive Disorder. Justine M. Kent, M.D. Senior Director, Janssen R&D
Clinical Perspective on Conducting Trials in Major Depressive Disorder Justine M. Kent, M.D. Senior Director, Janssen R&D Utility of the partial response construct In general, published clinical guidelines
More informationOpioid Step Policy. Description. Section: Prescription Drugs Effective Date: April 1, 2018
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Opioid Step Policy Page: 1 of 6 Last Review Date: March 16, 2018 Opioid Step Policy Description
More informationAAPS Views on Bioanalytical Method Validation Harmonization (on Behalf of AAPS Bioanalytical Community)
AAPS Views on Bioanalytical Method Validation Harmonization (on Behalf of AAPS Bioanalytical Community) Faye Vazvaei, Roche Innovation Center New York The 8th JBF Meeting, 8-9 February 2017 Background
More informationRule Governing the Prescribing of Opioids for Pain
Rule Governing the Prescribing of Opioids for Pain 1.0 Authority This rule is adopted pursuant to Sections 14(e) and 11(e) of Act 75 (2013) and Sections 2(e) and 2a of Act 173 (2016). 2.0 Purpose This
More informationPediatric Extrapolation in FDA Submissions Sources of Data
Pediatric Extrapolation in FDA Submissions Sources of Data Gilbert Burckart, Pharm.D. Associate Director of Pediatrics Office of Clinical Pharmacology Office of Translational Sciences, CDER 1 Pediatric
More informationStandardization for Preclinical Evaluation of Influenza Vaccines in Animal Models - WHO activities
Standardization for Preclinical Evaluation of Influenza Vaccines in Animal Models - WHO activities 2 nd WHO Integrated Meeting on development and clinical trials of Influenza vaccines that induce broadly
More informationBasic Standards for Osteopathic Fellowship Training in Sleep Medicine
Basic Standards for Osteopathic Fellowship Training in Sleep Medicine American Osteopathic Association and the American College of Osteopathic Neurologists and Psychiatrists and the American College of
More informationAddressing the Challenge of ENDS Regulation. David Graham President & Managing Partner Reveritas Group
Addressing the Challenge of ENDS Regulation David Graham President & Managing Partner Reveritas Group Addressing the Challenge of ENDS Regulation 1. The context of conflict and effect of the crossfire
More informationWhat's Important to Consider When Developing a Complex Generic Drug? September 5, 2018
What's Important to Consider When Developing a Complex Generic Drug? September 5, 2018 Session Description FDA has provided drug manufacturers tools to assist the development of complex generic drugs to
More informationT E C H N O L O G Y INTRODUCTION F I G U R E 1 F I G U R E 2
ABUSE DETERRENT T E C H N O L O G Y New Abuse Deterrent Formulation (ADF) Technology for Immediate-Release Opioids By: Johannes Bartholomäus, PhD; Sebastian Schwier, PhD; Martin Brett, Hans-Jürgen Stahlberg,
More informationSpontaneous canine malignancies: Models for precision cancer medicine
National Cancer Institute Spontaneous canine malignancies: Models for precision cancer medicine Amy K. LeBlanc, DVM DACVIM (Oncology) Director, NCI Comparative Oncology Program NIH/NCI Center for Cancer
More informationADDICTION STUDIES (ADST)
Addiction Studies (ADST) 1 ADDICTION STUDIES (ADST) ADST 196. EXPERIMENTAL COURSE. 1-5 ADST 300. SURVEY OF ALCOHOL/DRUG PROBLEMS. 4 Students will learn international and current definitions of alcohol
More informationThe role of JECFA for CCFA
The role of JECFA for CCFA How does JECFA perform safety assessments: scope, data needs, process and outcome Angelika Tritscher, WHO Secretary JECFA Markus Lipp, FAO Secretary JECFA Overview Introduction
More informationNeonatal Abstinence Syndrome (NAS)
Neonatal Abstinence Syndrome (NAS) Jodi Jackson, MD Neonatologist Children's Mercy Hospital Associate Professor of Pediatrics University of Missouri-Kansas City School of Medicine Medical director NICU
More informationOpioid Prescribing Improvement Program
Opioid Prescribing Improvement Program Jeff Schiff, MD, MBA, Medical Director of Minnesota Health Care Programs Sarah Rinn, MPH, Opioid Prescribing Improvement Program Coordinator Agenda Opioid Prescribing
More informationEXTENDED RELEASE OPIOID DRUGS
RATIONALE FOR INCLUSION IN PA PROGRAM Background Hydrocodone (Hysingla ER, Vantrela ER, Zohydro ER), hydromorphone (Exalgo), morphine sulfate (Arymo ER, Avinza, Embeda, Kadian, MorphaBond, MS Contin),
More informationUPDATE ON PREMARKET TOBACCO PRODUCT AUTHORIZATION PATHWAY
UPDATE ON PREMARKET TOBACCO PRODUCT AUTHORIZATION PATHWAY Presented by Ii-Lun Chen, M.D Director Division of Individual Health Science Office of Science, CTP, FDA Disclaimer: This is not a formal dissemination
More informationAAM Fall Tech Conference November 6-8, 2017 Rockville, MD
AAM Fall Tech Conference 2017 November 6-8, 2017 Rockville, MD Excipients Breakout Session Highlights of FDA-USP workshop on Critical Importance of Excipients in Drug Development Why Excipients are Important
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationFood Labeling and Sugars
Food Labeling and Sugars Kathleen Ellwood, Ph.D. Director, Nutrition Programs Staff Office of Nutrition, Labeling and Dietary Supplements Center for Food Safety and Applied Nutrition-FDA Revision of Reference
More informationBuilding innovative drug discovery alliances. Hepatic uptake and drug disposition o in vitro and in silico approaches
Building innovative drug discovery alliances Hepatic uptake and drug disposition o in vitro and in silico approaches Dr Beth Williamson Evotec AG, 2017 Outline Importance of predicting clearance In vitro
More informationLupus: Patient Voices. Report Overview March 6, 2018
Lupus: Patient Voices Report Overview March 6, 2018 Welcome Kathleen Arntsen, Lupus and Allied Diseases Association Sandra Raymond, Lupus Foundation of America Diane Gross, Lupus Research Alliance 2 Goals
More informationPSYCHIATRY. THE POWER OFx. Experts. Experience. Execution. A Deeper Dive into Psychiatry. Scientifically-Driven Clinical Development
THE POWER OFx Experts. Experience. Execution. A Deeper Dive into Psychiatry Incidences of mental disorders such as depression, bipolar, anxiety disorders, and schizophrenia continue to grow around the
More informationGoToWebinar Housekeeping: Attendee participation
GoToWebinar Housekeeping: Attendee participation Your Participation Join audio: Choose Mic & Speakers to use your computer for audio. Not recommended for desktop units but works with laptops If not using
More informationSBIRT Collaborative: Wednesday, May 11, PM EST Dial-in information: (800) ;
SBIRT Collaborative: Improving Access to Prevention and Early Intervention Services for Youth Substance Use Disorders Wednesday, May 11, 2016 4 PM EST Dial-in information: (800) 326-0013; 1933125 Funded
More informationBuprenorphine Access in California
Buprenorphine Access in California James J. Gasper, PharmD, BCPP Pharmacy Benefits Division Department of Health Care Services james.gasper@dhcs.ca.gov Source: CDPH Vital Statisitics Death Statistical
More informationScience for All, All for Science Scientific Achievements of ILSI Europe
Science for All, All for Science Scientific Achievements of ILSI Europe ILSI Europe 2013 Annual Symposium 26-27 March 2013, Brussels, Belgium Prof. Diána Bánati Executive and Scientific Director, ILSI
More informationKeyzilen TM Program Update
Keyzilen TM Program Update October 11, 2016 Forward-looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial risks and uncertainties.
More informationThe Tobacco Control Act s Premarket Review Authorities: Reports on Substantial Equivalence and Exemption Requests (905(j))
The Tobacco Control Act s Premarket Review Authorities: Reports on Substantial Equivalence and Exemption Requests (905(j)) January 12, 2011 Cristi Stark, MS Senior Regulatory Health Project Manager Office
More informationRegulatory Experience in Reviewing CV Safety for Diabetes
Regulatory Experience in Reviewing CV Safety for Diabetes Drugs Kristina Dunder MD, PhD, Alternate CHMP member MPA, Sweden Disclaimer The views and opinions expressed in the following PowerPoint slides
More information